

Anti-ADC Antibody Antibody (Cantuzumab)

Introduction

Cantuzumab is a monoclonal antibody designed to target and bind to specific antigens on the surface of cancer cells. It belongs to a class of therapeutics called antibody-drug conjugates (ADCs), which combine the targeting capabilities of monoclonal antibodies with the cancer-killing ability of cytotoxic drugs. Cantuzumab specifically targets the CanAg antigen, which is often overexpressed in certain types of cancer, such as colorectal cancer, pancreatic cancer, and certain types of lung cancer. By binding to this antigen, Cantuzumab can deliver its cytotoxic payload directly to cancer cells, thereby minimizing damage to healthy cells and increasing the effectiveness of treatment.

Product parameters

Alternative Names	huC242, huC242-DM4
Target Accession	-
Target	ADC Antibody
CAS number	1204740-23-7
Molecular Weight	-
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	1 mg/mL
Buffer System	100 mM Pro 20 mM Arg pH 5.0.
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C

Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.



1. This product is for scientific research use only.



APExBIO Technology
www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

